AVAX TECHNOLOGIES ANNOUNCES THE COMMENCEMENT OF TWO CLINICAL TRIALS

AVAX Technologies has initiated enrollment for its clinical trial of M-Vax for the treatment of patients with Stage III and IV melanoma. The U.S. study is a multicenter trial that will include up to seven clinical sites.

In addition, AVAX has initiated a clinical trial in patients with metastatic peritoneal cancer in France. Both studies will measure safety and include an immunological measure of vaccine activity as measured by Delayed Type Hypersensitivity Testing.